Panbela Therapeutics is a biotechnology business based in the US. Panbela Therapeutics shares (PBLA) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.24 – a decrease of 5.2% over the previous week. Panbela Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.24 |
|---|---|
| 52-week range | $0.23 - $1.11 |
| 50-day moving average | $0.32 |
| 200-day moving average | $0.36 |
| Wall St. target price | $500.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-34.51 |
Historical closes compared with the close of $0.245 from 2025-05-22
| 1 week (2025-05-16) | -2.00% |
|---|---|
| 1 month (2025-04-24) | -23.20% |
| 3 months (2025-02-24) | -41.67% |
| 6 months (2024-11-22) | -29.84% |
| 1 year (2024-05-24) | -31.94% |
|---|---|
| 2 years (2023-05-24) | -99.89% |
| 3 years (2022-05-24) | 34800 |
| 5 years (2020-05-22) | 124800 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -229.77% |
| Return on equity TTM | -798.16% |
| Profit margin | 0% |
| Book value | $-3.74 |
| Market Capitalization | $1.2 million |
TTM: trailing 12 months
We're not expecting Panbela Therapeutics to pay a dividend over the next 12 months.
Panbela Therapeutics's shares were split on a 1:20 basis on 17 January 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Panbela Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Panbela Therapeutics shares which in turn could have impacted Panbela Therapeutics's share price.
Over the last 12 months, Panbela Therapeutics's shares have ranged in value from as little as $0.234 up to $1.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Panbela Therapeutics's is 1.274. This would suggest that Panbela Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Panbela Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
These are the stocks to buy when you don’t have much to spend.
A deep dive into the highlights and limitations of Frec.
It can help reduce taxes owed, but it’s not for beginners.
Compare pros, cons, research tools and reviews for these two trading platforms.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.